SCHEMBL784929

SCHEMBL784929

CN(CCC1CCNCC1)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.53
CARM1 Q86X55 1/20 0.49
PRMT6 Q96LA8 1/20 0.49
PRMT8 Q9NR22 1/20 0.49
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
BCHE P06276 4/20 0.46
ACHE P22303 3/20 0.46
SIGMAR1 Q99720 1/20 0.45
DRD2 P14416 1/20 0.43
ALDH1A1 P00352 1/20 0.42
MAOB P27338 2/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7957515 0.90 SIGMAR1 (0.53) GBA1CARM1PRMT6PRMT8SLC6A2
SCHEMBL5651526 0.84 GBA1 (0.56) GBA1CARM1PRMT6PRMT8SLC6A2
SCHEMBL784983 0.84 GBA1 (0.56) GBA1SLC6A2SLC6A4SIGMAR1MAOB
Hydrochloric Acid SCHEMBL22407358 0.78 MEN1 (0.50) GBA1SLC6A2SLC6A4ACHE
SCHEMBL784816 0.76 ACHE (0.53) BCHEACHE
SCHEMBL5649396 0.75 GBA1 (0.53) GBA1SLC6A2SLC6A4SIGMAR1DRD2
SCHEMBL26668497 0.75 EP300 (0.46) GBA1SLC6A2SLC6A4
SCHEMBL26456593 0.75 ACHE (0.52) BCHEACHE
Trifluoroacetic Acid SCHEMBL785809 0.75 SLC6A2 (0.46) GBA1SLC6A2SLC6A4ITGB3ITGA2B
SCHEMBL2241250 0.74 GBA1 (0.66) GBA1CARM1PRMT6SLC6A4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119894895-A IRAK4 degradation agent and application thereof 领泰生物医药(绍兴)有限公司 2025-04-25 CN disclosed
CN-115710274-A IRAK4 degradation agent, preparation method and application thereof 上海领泰生物医药科技有限公司 2023-02-24 CN disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
EP-2619178-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2013-07-31 EP disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
CN-1805951-A Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-19 CN disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed
EP-0720602-A1 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS KNOLL AG (DE) 1996-07-10 EP disclosed
WO-1995008535-A1 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS KNOLL AG (DE) 1995-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC GBA1 173/4885CARM1 455/4885PRMT6 313/4885
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 GBA1 849/4885CARM1 3153/4885PRMT6 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.